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HIGHLY LIPOPHILIC CAMPTOTHECIN 
INTERMEDIATES AND PRODRUGS AND 
METHODS OF PREPARATION THEREOF 
This application claims the bene?t of Us. Provisional 
Patent Application Ser. No. 60/469,805 ?led on May 12, 
2003. 
This invention Was made With Government support under 
NIH Grant Number lR0lCA63653. The Government may 
have certain rights in this invention. 
5 
2 
nicks are converted to irreversible and lethal double strand 
DNA breaks during replication. 
The camptothecin class of anticancer agents have exhib 
ited unusual reactivity in vivo, both With respect to drug 
hydrolysis and blood protein interactions. These factors 
have hindered the pharmaceutical development and clinical 
implementation of camptothecins. In terms of hydrolysis, 
each of the camptothecins shoWn in Table 1 contains an 
ot-hydroxy-o-lactone pharmacophore. 
TABLE 1 
Clinical candidates and FDA-approved analogs in the camptothecin family of antiturnor agents 
Aqueous 
Solubility Compound R10 R1 R2 R3 
Soluble Topotecan/TPT H CH2NH(CH3)2 OH H 
" CDK602 H C2H5NHCH(CH3)2 H H 
Irinotecan/CPT- ll C2H5 H O H 
GI-l472llC/GG-2ll H O 
\ 
— CH2 — N N — CH3 
0/ 
Insoluble Camptothecin H H H H 
" 9-AC H NH2 H H 
9-NC/Rubitecan H N02 H H 
SN-3 8 C2H5 H OH H 
DB-67 Si(CH3)2C(CH3)3 H OH H 
MDCPT H H <O— 
O— 
TECHNICAL FIELD 
The present invention relates to novel intermediates and 
prodrugs of highly lipophilic 7-silylalkylcamptothecins (si 
latecans). 
BACKGROUND OF THE INVENTION 
Camptothecin and related analogs (Table l) are emerging 
as a prominent class of agents useful in the treatment of 
cancer. The camptothecins display a unique mechanism of 
action: stabiliZation of the covalent binding of the enZyme 
topoisomerase I (topo I), an intranuclear enZyme that is 
overexpressed in a variety of tumor lines, to DNA. This 
drug/enZyme/DNA complex leads to reversible, single 
strand nicks. According to the fork collision model, the DNA 
60 
65 
At physiological pH of 7 and above this functionality is 
reactive, readily converting to the biologically inactive “ring 
opened” carboxylate form. Thus, as a result of the labile 
ot-hydroxy-o-lactone pharmacophore, an equilibrium is 
established betWeen tWo distinct drug species: 1) the bio 
logically active lactone form Where the lactone ring remains 
closed; and 2) a biologically-inactive carboxylate form 
generated upon the hydrolysis of the lactone ring of the 
parent drug. 
This hydrolysis problem With camptothecin and many 
analogs (e.g. 9-aminocamptothecin, 9-nitrocamptothecin) is 
exacerbated in human blood. In human blood and tissues, 
the camptothecin equilibrium of active lactone form vs. 
inactive carboxylate form can be strongly modulated by the 
presence of human serum albumin (HSA). The lactone form 
US 7,064,206 B1 
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of camptothecin binds to HSA With moderate af?nity yet the 
carboxylate form of camptothecin binds much more tightly 
than the carboxylate, displaying the l50-fold enhancement 
in its a?inity. Thus, the preferential binding of the carboxy 
late form to HSA drives the equilibrium to the right in favor 
of the carboxylate, resulting in the lactone ring hydrolyZing 
more rapidly and completely (than When camptothecin is in 
an aqueous solution Without HSA). 
The development of 7-silylcamptothecins (or silatecans) 
has resulted in the identi?cation of agents With improved 
human blood stabilities and activities. Recent rational design 
efforts have resulted in the identi?cation of A,B-ring modi 
?ed camptothecins displaying improved human blood sta 
bilities combined With potent anti-topoisomerase I activities. 
Dual 7,10-substitution (Where the l0-substituent is a 
hydroxy group) results in camptothecins displaying vastly 
improved human blood stabilities. SN-38 contains this dual 
7-alkyl-l0-hydroxy substitution pattern and in 1994 it Was 
shoWn that these structural modi?cations block SN-38 from 
associating With the high affinity camptothecin carboxylate 
binding pocket on HSA. 
More recently the design of another dual 7,10-modi?ed 
camptothecin has been described. The neW agent is 7-t 
butyldimethylsilyl-lO-hydroxycamptothecin (DB-67). 
DB-67 displays markedly improved human blood stability 
and potent anti-topoisomerase I anticancer activity. The 
design of DB-67 Was based upon the folloWing tWo consid 
erations: 1) dual 7,10-substitution patterns eliminate the 
highly speci?c binding of carboxylate form over lactone 
form by HSA; and 2) lactone stabiliZation is further pro 
moted by enhanced lipophilicity or lipid bilayer partitioning. 
Lipophilicity promotes camptothecin drug stability by 
favoring lactone partitioning into blood cells, thereby pro 
tecting the active lactone forms from hydrolysis. The key 
ot-hydroxy-o-lactone pharmacophore in DB-67 displays 
superior stability in human blood When compared With 
FDA-approved topotecan, CPT-ll, and several other clini 
cally relevant camptothecin analogs. DB-67 displayed a tl/2 
of 130 min. and a % lactone at equilibrium value of 30 in 
human blood; the t-butyldimethylsilyl group enhances lipo 
philicity and thereby promotes drug associations With blood 
cells. DB-67 is 25 times lipophilic than camptothecin and 
readily incorporates as its active lactone form into cellular 
and liposomal bilayers. Equally important, the dual 7-alkyl 
silyl and l0-hydroxy substitution in DB-67 blocks the 
associations of the carboxylate form of DB-67 With the high 
af?nity carboxylate binding pocket on HSA. Together, the 
enhanced lipophilicity and altered HSA interactions provide 
DB-67 With the highest human blood stability When com 
pared With clinically relevant camptothecins containing the 
conventional ot-hydroxy-o-lactone pharmacophore. 
In vitro cytotoxicity assays have shoWn that DB-67 is of 
comparable potency relative to camptothecin and l0-hy 
droxycamptothecin, as Well as the FDA approved analogs 
topotecan and CPT-ll. In addition, cell-free cleavage assays 
reveal that DB-67 forms more stable topoisomerase I cleav 
age complexes than camptothecin or SN-38. In terms of in 
vitro potency, DB-67 has been shoWn to display activity 
against human glioma in a murine model. Overall, these 
stability and activity pro?les of DB-67 indicate hoW rational 
drug design can result in neW, highly lipophilic agents 
displaying improved pharmacological properties. 
In this invention We describe novel, highly lipophilic 
intermediates and prodrugs of DB-67 and other silatecans. 
DETAILED DESCRIPTION OF THE 
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4 
INVENTION 
Our previous rational synthetic efforts described above 
yielded a series of silatecan agents. 7-t-Butyldimethylsilyl 
l0-hydroxycamptothecin, Which We have termed DB-67, is 
an example of a silatecan that displays improved biological 
properties. In the current invention We describe novel inter 
mediates and prodrugs of DB-67 and related 7-silylcamp 
tothecins or silatecans. 
The invention includes compounds With the folloWing 
structures A and B: 
R1 
R1 
wherein R1 and R2 are independently the same or different 
and are hydrogen, an alkyl group, an alkenyl group, an 
alkynyl group, an alkoxy group, an aryloxy group, an 
acyloxy group, OC(O)ORl2 wherein R12 is an alkyl group, 
a carbamoyloxy group, a halogen, a hydroxy group, a nitro 
group, a cyano group, an aZido group, a formyl group, a 
hydraZino group, C(O)Rl3 wherein R13 is an alkyl group, an 
alkoxy group, an amino group or a hydroxy group, SRM, 
wherein R14 is hydrogen, C(O)Rl3 , an alkyl group, or an aryl 
group; or R1 and R2 together form a group of the formula 
O(CH2)PO Wherein p represents an integer 1 through 6; R3 
is H, a nitro group, a halogen atom, an amino group, a 
hydroxy group, or a cyano group, or R2 and R3 together form 
a group of the formula O(CH2)PO Wherein p represents an 
integer 1 through 6; R4 is H, F, an alkyl group, an alkenyl 
group, an alkynyl group, a trialkylsilyl group or an alkoxy 
group; R5 is a Cl_l5 alkyl group, an allyl group, a benZyl 
group or a propargyl group; R6, R7 and R8 are independently 
a Cl_l5 alkyl group, a C2_l5 alkenyl group, a C2_l5 alkynyl 
group, an aryl group or a (CH2) Rl5 group, Wherein q is an 
integer between 1 and 15 and R1 is a hydroxy group, alkoxy 
group, an amino group, an alkylamino group, a dialkylamino 
group, a halogen atom, a cyano group or a nitro group; R9 
is a hydrogen, an alkyl group, an alkenyl group, an alkynyl 
group, an alkoxy group, an aryloxy group, or an acyloxy 
group; R10 is an alkylene group, an alkenylene group or an 
alkynylene group. 
The invention also includes compounds With the folloW 
ing structures C and D: 
US 7,064,206 B1 
OH 
R1 
OH 
wherein R1 and R2 are independently the same or different 
and are hydrogen, an alkyl group, an alkenyl group, an 
alkynyl group, an alkoxy group, an aryloxy group, an 
acyloxy group, OC(O)ORl2 wherein R12 is an alkyl group, 
a carbamoyloxy group, a halogen, a hydroxy group, a nitro 
group, a cyano group, an aZido group, a formyl group, a 
hydraZino group, C(O)Rl3 wherein R13 is an alkyl group, an 
alkoxy group, an amino group or a hydroxy group, SRM, 
wherein R14 is hydrogen, C(O)Rl3 , an alkyl group, or an aryl 
group; or R1 and R2 together form a group of the formula 
O(CH2)PO Wherein p represents an integer 1 through 6; R3 
is H, a nitro group, a halogen atom, an amino group, a 
hydroxy group, or a cyano group, or R2 and R3 together form 
a group of the formula O(CH2)PO Wherein p represents an 
integer 1 through 6; R4 is H, F, an alkyl group, an alkenyl 
group, an alkynyl group, a trialkylsilyl group or an alkoxy 
group; R5 is a Cl_l5 alkyl group, an allyl group, a benZyl 
group or a propargyl group; R6, R7 and R8 are independently 
a Cl_l5 alkyl group, a C2_l5 alkenyl group, a C2_l5 alkynyl 
group, an aryl group or a (CH2) Rl5 group, Wherein q is an 
integer betWeen 1 and 15 and R1 is a hydroxy group, alkoxy 
group, an amino group, an alkylamino group, a dialkylamino 
group, a halogen atom, a cyano group or a nitro group; R9 
is a hydrogen, an alkyl group, an alkenyl group, an alkynyl 
group, an alkoxy group, an aryloxy group, or an acyloxy 
group; R10 is an alkylene group, an alkenylene group or an 
alkynylene group; R11 is (CH2)LNRl6Rl7 Wherein L may be 
an integer ranging from 1*30 and R16 and R17 are indepen 
dently the same or different and are hydrogen, a C1_l5 alkyl 
group, a C2_l5 alkenyl group, a C2_ 15 alkynyl group, an aryl 
group, a (CH2)YRl8 group, a (CH2)YC(O)Rl8 group or a 
(CH) YCO2R18 Wherein Y may be an integer ranging from 1 
to 15 and R18 is a hydroxy group, a thiol group, an alkylthiol, 
a silyl group, an alkoxy group, an amino group, an alky 
lamino group, a dialkylamino group, a halogen atom, a 
cyano group, a nitro group. R11 may also be a hydrogen, an 
alkyl group, an alkenyl group. 
All compounds of the present invention including the 
[3-hydroxylactone group can exist in racemic form, enantio 
merically enriched from, and enantiomerically pure form. 
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6 
The formulas of such compounds as set forth herein cover 
and/or include each such form. 
The terms “alkyl”, “aryl” and other groups refer generally 
to both unsubstituted and substituted groups unless speci?ed 
to the contrary. Unless otherWise speci?ed, alkyl groups are 
hydrocarbon groups and are preferably C liC 1 5 (that is, 
having 1 to 15 carbon atoms) alkyl groups, and more 
preferably CFC1O alkyl groups, and can be branched or 
unbranched, acyclic or cyclic. The above de?nition of an 
alkyl group and other de?nitions apply also When the group 
is a substituent on another group (for example, an alkyl 
group as a substituent of an alkylamino group or a dialky 
lamino group). The term “aryl” refers to phenyl or napthyl. 
As used herein, the terms “halogen” or “halo” refer to ?uoro, 
chloro, bromo and iodo. 
The term “alkoxy” refers to 4ORd, Wherein Rd is an alkyl 
group. The term “aryloxy” refers to iORe, Wherein Re is an 
aryl group. The term acyl refers to iC(O)Rf. The term 
“alkenyl” refers to a straight or branched chain hydrocarbon 
group With at least one double bond, preferably With 2*15 
carbon atoms, and more preferably With 2*10 carbon atoms 
(for example, 4CH=CHRg or iCH2CH=CHRg). The 
term “alkynyl” refers to a straight or branched chain hydro 
carbon group With at least one triple bond, preferably With 
2*15 carbon atoms, and more preferably With 2*10 carbon 
atoms (for example, 4CECRh or ‘CH2 CECRh). The terms 
“alkylene,” “alkenylene” and “alkynylene” refer to bivalent 
forms of alkyl, alkenyl and alkynyl groups, respectively. 
The groups set forth above, can be substituted With a Wide 
variety of substituents to synthesiZe homocamptothecin ana 
logs retaining activity. For example, alkyl groups may 
preferably be substituted With a group or groups including, 
but not limited to, a benZyl group, a phenyl group, an alkoxy 
group, a hydroxy group, an amino group (including, for 
example, free amino groups, alkylamino, dialkylamino 
groups and arylamino groups), an alkenyl group, an alkynyl 
group and an acyloxy group. In the case of amino groups 
(iNRaRb), R“ and Rh are preferably independently hydro 
gen, an acyl group, an alkyl group, or an aryl group. Acyl 
groups may preferably be substituted With (that is, Rf is) an 
alkyl group, a haloalkyl group (for example, a per?uoroalkyl 
group), an alkoxy group, an amino group and a hydroxy 
group. Alkynyl groups and alkenyl groups may preferably 
be substituted With (that is, Rg and Rh are preferably) a group 
or groups including, but not limited to, an alkyl group, an 
alkoxyalkyl group, an amino alkyl group and a benZyl 
group. 
The term “acyloxy” as used herein refers to the group 
4OC(O)Rd. 
The term “alkoxycarbonyloxy” as used herein refers to 
the group 4OC(O)ORd. 
The term “carbamoyloxy” as used herein refers to the 
group wc(o)NR“Rb. 
Amino and hydroxy groups may include protective 
groups as knoWn in the art. Preferred protective groups for 
amino groups include tert-butyloxycarbonyl, formyl, acetyl, 
benZyl, p-methoxybenZyloxycarbonyl, trityl. Other suitable 
protecting groups as knoWn to those skilled in the art are 
disclosed in Greene, T., Wuts, P. G. M., Protective Groups 
in Organic Synthesis, Wiley (1991), the disclosure of Which 
is incorporated herein by reference. 
In general, R1, R2 and R3 are preferably not excessively 
bulky to maintain activity of the resultant camptothecin 
analog. Preferably, therefore, R1, R2 and R3 independently 
have a molecular Weight less than approximately 250. More 
preferably R1, R2 and R3 independently have a molecular 
Weight less than approximately 200. 
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Some of the camptothecin analogs of the present inven 
tion can be prepared for pharmaceutical use as salts With 
inorganic acids such as, but not limited to, hydrochloride, 
hydrobromide, sulfate, phosphate, and nitrate. The camp 
tothecin analogs can also be prepared as salts With organic 
acids such as, but not limited to, acetate, tartrate, fumarate, 
succinate, citrate, methanesulfonate, p-toluenesulfonate, and 
stearate. Other acids can be used as intermediates in the 
preparation of the compounds of the present invention and 
their pharmaceutically acceptable salts. 
For puri?cation, administration or other purposes, the 
E-ring (the lactone ring) may be opened With alkali metal 
such as, but not limited to, sodium hydroxide or calcium 
hydroxide, to form opened E-ring analogs of compounds of 
the present invention. The intermediates thus obtained are 
more soluble in Water and may be puri?ed to produce, after 
treatment With an acid, a puri?ed form of the camptothecin 
analogs of the present invention. 
All the novel compounds of the present invention Whether 
in racemic, enantiomerically enriched or enantiomerically 
pure form display good biological activity While also pos 
sessing favorable characteristics for active loading into 
liposomal particle drug delivery systems of the micelle type 
disclosed and described in Us. Pat. Nos. 5,316,771; 5,552, 
156 and 5,736,156. Pre-made liposomes can be ef?ciently 
loaded With any of the novel compounds of this invention 
using pH gradients. 
In brief, in the active core loading process an amine 
containing agent is loaded into the particle. For example, a 
gradient created by ammonia gas diffusing out of the lipo 
some particle can result in diffusion or active loading of the 
compound/agent of the present invention inWard to the core 
of the particle. The chemical gradient across the membrane 
creates a driving force for the compound/ agent to replace the 
lost NH3 from the interior of the liposome. Once inside the 
acidic con?nes of the core, the compound/agent becomes 
protonated and remains Within the core, as its positive 
charge impedes retro-diffusion across the liposome bilayer. 
The protonated amine also prevents the occurrence of 
nucleophilic attack of the amine on the lactone carbonyl. As 
liposomes can be actively and/or passively targeted to the 
tumor, the liposome encapsulated compound/agent can be 
effectively concentrated at the tumor site, therby reducing 
exposure of the healthy host tissues to the cytotoxic agent 
yet enhancing exposure at the tumor target. 
The tumor targeted approach involving liposomal deliv 
ery of core loaded compound/agent addresses multiple clini 
cal issues. For example, reduced systemic toxicity can be 
achieved. Enhanced exposure at the tumor site in terms of 
relative amounts of drug reaching the tumor can also be 
achieved. Furthermore, enhanced exposure at the tumor site 
can be achieved in terms of prolonging the exposure of drug 
there. 
The present invention also provides a method of treating 
a patient, Which comprises administering a pharmaceutically 
effective amount of a compound of the present invention. 
The compound may, for example, be administered to a 
patient a?licted With cancer and/or leukemia. The com 
pounds of the present invention may also act as antiviral (for 
example, anti-HIV) agents and antiparasitic agents. The 
pharmaceutically effective amount or dosage is preferably 
betWeen 0.01 to 80 mg of one of the compounds of structures 
A, B and/or C per kg of body Weight. More preferably, the 
pharmaceutically effective amount or dosage is preferably 
betWeen 0.1 to 40 mg of one or more of the compounds per 
kg of body Weight. In general, a pharmaceutically effective 
amount or dosage contains an amount of one of the com 
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pounds effective to display antileukemic and/or antitumor 
(anticancer) behavior. Pharmaceutical compositions con 
taining as an active ingredient of one of the compounds of 
the present invention including a pharmaceutically accept 
able salt thereof in association With a pharmaceutically 
acceptable carrier or diluent are also Within the scope of the 
present invention. 
The novel compounds of the present invention display 
good biological activity While also possessing favorable 
characteristics for active loading into liposomal particle drug 
delivery systems of the micelle type disclosed and described 
in Us. Pat. Nos. 5,316,771; 5,552,156 and 5,736,156. 
Pre-made liposomes can be ef?ciently loaded With the novel 
compounds of this invention using pH gradients. 
In brief, in the active core loading process an amine 
containing agent is loaded into the particle. For example, a 
gradient created by ammonia gas diffusing out of the lipo 
some particle can result in diffusion or active loading of the 
compound/agent of the present invention inWard to the core 
of the particle. The chemical gradient across the membrane 
creates a driving force for the compound/ agent to replace the 
lost NH3 from the interior of the liposome. Once inside the 
acidic con?nes of the core, the compound/agent becomes 
protonated and remains Within the core, as its positive 
charge impedes retro-di?‘usion across the liposome bilayer. 
The protonated amine also prevents the occurrence of 
nucleophilic attack of the amine on the lactone carbonyl. As 
liposomes can be actively and/or passively targeted to the 
tumor, the liposome encapsulated compound/agent can be 
effectively concentrated at the tumor site, therby reducing 
exposure of the healthy host tissues to the cytotoxic agent 
yet enhancing exposure at the tumor target. 
The tumor targeted approach involving liposomal deliv 
ery of core loaded compound/agent addresses multiple clini 
cal issues. For example, reduced systemic toxicity can be 
achieved. Enhanced exposure at the tumor site in terms of 
relative amounts of drug reaching the tumor can also be 
achieved. Furthermore, enhanced exposure at the tumor site 
can be achieved in terms of prolonging the exposure of drug 
there. 
The compounds of the present invention may be admin 
istered in a dose Which is effective at inhibiting the enZyme 
topoisomerase I. These amounts are generally from about 
1*80 mg/kh of body Weight per Week, preferably about 2*40 
mg/kg per Week. 
The compounds of the present invention may be admin 
istered as a pharmaceutical composition containing the 
compounds and a pharmaceutically acceptable carrier or 
diluent. The compounds can be administered as their ring 
open salt forms, since relactoniZation to their active forms 
can occur in the body (especially at sites of reduced pH). The 
active material can also be mixed With other active materials 
Which do not impair the desired action and/or supplement 
the desired action. The compounds/active materials accord 
ing to the present invention can be administered by any 
route, for example, orally, nasally, parenterally, intrave 
nously, intradermally, subcutaneously, or topically, in liquid 
or solid form. 
For the purposes of parenteral therapeutic administration, 
the active ingredient may be incorporated into a solution or 
suspension. The solutions or suspensions may also include 
the folloWing components: a sterile diluent such as Water: 
for injection, suspensions of liposomal particles Whereby the 
particles contain stable, active drug Within the core of the 
particle in a pH controlled and protected environment or 
associated to the outside of the particle or any of the bilayers 
of the particle, saline solution, ?xed oils, polyethylene 
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glycols, glycerine, propylene glycol or other synthetic sol 
vents; antibacterial agents such as benZyl alcohol or methyl -c0minued 
parabens; antioxidants such as ascorbic acid or sodium 
bisul?te; chelating agents such as ethylenediaminetetraace 
tic acid; bulfers such as acetates, citrates or phosphates and 5 
agents for the adjustment of tonicity such as sodium chloride 
or dextrose. The parenteral preparation can be enclosed in 
ampoules, disposable syringes or multiple dose vials made 0 
of glass or plastic. 10 HokvgNHBoc 
Another mode of administration of the compounds of this n : 1,2,3 
invention is oral. Oral compositions Will generally include 
an inert diluent or an edible carrier. They may be enclosed 
in gelatin capsules or compressed into tablet. For the pur 
pose of oral therapeutic administration, the aforesaid com- 15 
pounds may be incorporated With excipients and used in the 
form of tablets, troches, capsules, elixirs, suspensions, syr 
ups, Wafers, cheWing gums and the like. 
—> 
EDCl, DMAP, cnzcl2 
The tablets, pills, capsules and the like may contain the 
folloWing ingredients: a binder such as microcrystalline 
cellulose, gum tragacanth or gelatin; an excipient such as 
starch or lactose, a disintegrating agent such as alginic acid, 
Primogel, corn starch and the like; a lubricant such as 
magnesium stearate or Sterotes; a glidant such a colloidal 
silicon dioxide; and a sWeetening agent such as sucrose or 
saccharin or ?avoring agent such as peppermint, methyl 
salicylate, or orange ?avoring may be added. When the 
dosage unit is in the form of a capsule, it may contain, in 
addition to material of the above type, a liquid carrier such 
as a fatty oil. Other dosage unit forms may contain other 
various materials Which modify the physical form of the 
dosage unit, for example, as coatings. Thus tablets or pills 
may be coated With sugar, shellac, or other enteric coating 
agents. A syrup may contain, in addition to the active 
compounds, sucrose as a sWeetening agent and certain 
preservatives, dyes and coloring and ?avors. Materials used 
in preparing these various compositions should be pharma 
ceutically or veterinarally pure and non-toxic in the amount u 
used. 40 o NHBOC 
The folloWing examples are presented to further illustrate 
the invention, but it is not to be considered as limited thereto. 
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45 
Preparation of DB-67 20(S) uu-aminoalkanoanic 
esters 
DB-67 uu-aminoalkanoanic esters Were synthesiZed as 
folloWing: 50 
55 
MOMCl, DIPEA 
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DB-67 (1 equiv) Was dissolved in anhydrous dichlo 
romethane, and DIPEA (5 equiv) Was added under nitrogen 
atmosphere. The reaction mixture Was stirred for 10 min at 
room temperature followed by the addition of MOMCI (5 
equiv). The resulting solution Was left stirring overnight. 
The reaction Was terminated. Then the reaction mixture Was 
diluted by dichloromethane and Washed several times With 
Water, dried (MgSO4), ?ltered, and concentrated. Puri?ca 
tion by chromatography on silica gel gave 10-MOM pro 
tected compound. 
1-Ethyl-3 -(3 -dimethylaminopropyl)carbodiimide (EDCI, 
3 equiv) Was sloWly added to a solution of 10-MOM 
protected compound (1 equiv), N-tert-butoxycarbonylamino 
acid (3 equiv) and 4-(Dimethylamino)pyridine (DMAP, 0.6 
equiv) and anhydrous dichloromethane, Which had been 
pre-cooled to 00 C. The resulting solution Was alloWed to 
Warm to room temperature and stirred overnight. The 
organic fraction Was Washed With HCl (0.1 N) and Water and 
then extracted several times With CH2Cl2. Organic layers 
Were combined and dried With MgSO4, folloWed by ?ltra 
tion and concentration. Puri?cation of this residue by ?ash 
chromatography on silica gel gave chloromethyl methyl 
ether (MOM) and N-BOC protected prodrug. Deprotection 
of MOM and N-BOC groups Was achieved simultaneously 
by stirring MOM and N-BOC protected prodrug in dichlo 
romethane and tri?uoracetic acid for 30 minutes at room 
temperature, folloWed by concentration under high vacuum 
and recrystaliZation in methanol and ethyl ether. Purity of 
?nal products Was determined by HPLC and prodrug purity 
Was found to be greater than 98% pure. 
EXAMPLE 2 
Synthesis of DB-67 20-O-ester of N-methylglycine, 
mono (tri?uoroacetate) 
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-continued 
/ 0 ,CH3 YE “CF3COOH 
O 
A solution of 7-t-butyldimethylsilyl-10-MOM-hydroxy 
20(s)-CPT (100 mg, 0.19 mmol), N-(tert-butoxycarbonyl) 
metylyglycine (90 mg, 0.48 mmol) and DMAP (14 mg, 0.12 
mmol) in 10 ml anhydrous dichloromethane Was cooled to 
00 C., folloWed by the addition of EDCI (110 mg, 0.57 
mmol). The reaction mixture Was alloWed to come to room 
temperature and monitored by TLC. The resulting solution 
Was Washed With HCl (5 ml, 0.1 N) and Water, then extracted 
With dichloromethane. The organic layer Was dried With 
MgSO4, then ?ltered and concentrated. Puri?cation by col 
umn chromatography on silica gel (CH2Cl2iCH3COCH3, 
95:5) gave yelloW solid (120 mg, 90%). lHNMR (400 MHZ, 
CDCl3): 0.70 (s, 6H), 1.01 (m, 12H), 1.45 (d, 1:48, 9H), 
2.1(%2.34 (m, 2H), 2.96 (s, 3H), 3.54 (s, 3H), 4.05431 (AB 
system, 2H), 5.27 (m, 2H), 5.32 (s, 2H), 5375.42 (A ofAB 
system, 1H), 56845.72 (B ofAB system, 1H), 7.13, 7.30 (ss, 
1H), 74647.51 (m, 1H), 79147.94 (dd, 1:64, 1:24, 1H), 
8.054816 (dd, 1:328, 1:92, 1H). 7-t-butyldimethylsilyl 
10-MOM-hydroxy-20(s)-CPT-20-O-ester of N-tert-butoxy 
carbonylmethyglycine (100 mg, 0.14 mmol) Were dissolved 
in dichloromethane and tri?uoracetic acid, then stirred 30 
min. at room temperature. The yelloW solution Was concen 
trated under high vacuum. RecrystaliZation by methanol and 
ethyl ether obtained yelloW solid 86 mg, yield 90%. lHNMR 
(400 MHZ, CD30D): 0.73 (s, 6H), 1.02 (s, 9H), 1.08 (t, 
J:7.2, 1H), 42744.40 (q, 1:168, 2H), 5.35 (s, 2H), 
5475.51 (A of AB system, 1H), 5.634567 (B of AB 
system, 1H), 7.34 (s, 1H), 74247.45 (dd, 1:92, 1:12, 1H), 
7.67 (d, 1:28, 1H), 8.19 (d, 1:92, 1H). 
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EXAMPLE 3 
Conversion of DB-67 20(S) uu-aminoalkanoanic 
esters to lactam, ortho lactone and acetic acid 
prodrugs 
14 
Glycinate Ester of DB-67: R1 : Si(CH3)2C(CH3)3, R3 I OH 
At physiological pH of 7 or above, the nucleophilicity of 
the amine group of DB-67 20(S)-glycinate ester manifests 
itself and cycliZation to the C-21 carbonyl carbon occurs. 
This cycliZation triggers a rapid and convenient non-enZy 
matic decomposition process that releases active DB-67. 
DB-67 20(S)-glycinate 1 decomposed to produce several 
products: the closed-ring lactone form of DB-67 5, the 
ring-opened carboxylate form of DB-67 6, and tWo novel 
decomposition products 3 and 4 generated folloWing the 
formation of an unusual six membered morpholine 2,5 
dione ring 2 (or lactam intermediate). The lactam interme 
diate arose by intramolecular nucleophilic attack of the 
amino group on the lactone E-ring carbonyl carbon of 
DB-67 and is in fast equilibrium With structures 3 (Which We 
refer to as the ortho lactone) and 4. Ortho lactone 3 arose by 
a second intramolecular reaction Within the lactam interme 
diate and 3 exhibited the same mass as DB-6 20(S)-glycinate 
ester but With a strikingly different fragmentation pattern. 4 
arose by a competitive intermolecular reaction to the lactam 
intermediate and reacted to release both 5 and 6. ESl/MS/ 
MS shoWed that DB-67 glycinate ester fragmentation pat 
tern [m/Z(%)] Was: 536 (100%), 461 (50%), 433 (20%); 
DB-67 ortho lactone fragmentation pattern Was: 536 
(100%), 518 (10%). 
EXAMPLE 4 
Procedure for the isolation of the ortho lactone 
from N-methyl DB-67 glycinate ester 
N-methyl DB-67 glycinate tri?uoroacetic acid salt Was 
dissolved in DMF, 1.2 eq. triethylamine Was then added and 
reaction stirred overnight at room temperature. Organic 
solvent Was removed and a yelloW precipitate Was rinsed 
With Water, ?ltered, and dried under vacuum. Yield: 98%. 
EXAMPLE 5 
Loading of Compounds of Present Invention into 
Liposomes 
Remote “active” loading of prodrug into premade small 
unilamellar vesicles, With diameters of 100 nm, Was carried 
out by using transmembrane ammonium sulfate gradients. 
Prodrug Was added to a liposomal suspension Where initially 
[(NH4)2SO4]CORE' [(NH4)2SO4]EXTERNAL; loading of the 
prodrug occurred as a result of base exchange (initiated by 
NH3 gas molecules departing the liposome). Whereas 
underivatiZed camptothecin and DB-67 localiZe predomi 
nantly in the bilayer compartment of the liposome, their 
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20-OR prodrugs, Where R) CO[CH2]nNH 2 and n) 1*3, 
loaded With high ef?ciency (60 to 90%) into the core of 
liposomes at clinically relevant drug-to-lipid ratios (between 
1:4 to 1:20). More importantly, these core-loaded liposomal 
formulations of camptothecin 4-aminobutanoate ester and 
DB-67 4-aminobutanoate ester exhibited markedly 
improved stabilities in Whole blood relative to their free 
forms. Whereas the decomposition of free prodrug in both 
cases Was extensive, liposomal entrapment prevented the 
degradation process from occurring, providing indirect evi 
dence that the prodrug Was effectively retained Within the 
liposome for periods up to 40 h. These time periods are 
knoWn to be sufficient for successful tumor-targeting to be 
achieved. 
What is claimed is: 
1. A compound having the formula: 
R1 
OH 
wherein R1 and R2 are independently the same or different 
and are hydrogen, an alkyl group, an alkenyl group, an 
alkynyl group, an alkoxy group, a phenoxy group, a napthy 
loXy group, an acyloxy group, OC(O)ORl2 wherein R12 is an 
alkyl group, a carbamoyloxy group, a halogen, a hydroxy 
group, a nitro group, a cyano group, an aZido group, a formyl 
group, a hydraZino group, C(O)Rl3 wherein R13 is an alkyl 
group, an alkoxy group, an amino group or a hydroxy group, 
SR14, wherein R14 is hydrogen, C(O)Rl3, an alkyl group, a 
phenyl group or a napthyl group; R3 is H, a nitro group, a 
halogen atom, an amino group, a hydroxy group, or a cyano 
group; R4 is H, F, an alkyl group, an alkenyl group, an 
alkynyl group, a trialkylsilyl group or an alkoxy group; R5 
is a Cl_l5 alkyl group, an allyl group, a benZyl group or a 
propargyl group; R6, R7 and R8 are independently a Cl_l5 
alkyl group, a C2_ 15 alkenyl group, a C2_l5 alkynyl group, a 
phenyl group, a napthyl group or a (CH2)qRl5 group, 
Wherein q is an integer betWeen 1 and 15 and R15 is a 
hydroxy group, alkoxy group, an amino group, an alky 
lamino group, a dialkylamino group, a halogen atom, a 
cyano group or a nitro group; R9 is a hydrogen, an alkyl 
group, an alkenyl group, an alkynyl group, an alkoxy group, 
a phenoxy group, a napthyloxy group, or an acyloxy group; 
R10 is an alkylene group, an alkenylene group or an alky 
nylene group; R11 is hydrogen, an alkyl group, an alkenyl 
group and (CH2)LNRl6Rl7 Wherein L may be an integer 
ranging from 1*30 and R16 and R17 are independently the 
same or different and are hydrogen, a Cl_l5 alkyl group, a 
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C2_l5 alkenyl group, a C2_ 15 alkynyl group, a phenyl group, 
a napthyl group, a (CH2)YRl8 group, a (CH2)YC(O)Rl8 
group or a (CH2)YCO2Rl8 Wherein Y may be an integer 
ranging from 1 to 15 and R18 is a hydroxy group, a thiol 
group, an alkylthiol, a silyl group, an alkoxy group, an 
amino group, an alkylamino group, a dialkylamino group, a 
halogen atom, a cyano group, a nitro group. 
2. A compound having the formula: 
R1 
OH 
wherein R1 and R2 are independently the same or different 
and are hydrogen, an alkyl group, an alkenyl group, an 
alkynyl group, an alkoxy group, a phenoxy group, a napthy 
loXy group, an acyloxy group, OC(O)ORl2 wherein R12 is an 
alkyl group, a carbamoyloxy group, a halogen, a hydroxy 
group, a nitro group, a cyano group, an aZido group, a formyl 
group, a hydraZino group, C(O)Rl3 wherein R13 is an alkyl 
group, an alkoxy group, an amino group or a hydroxy group, 
SRM, wherein R14 is hydrogen, C(O)Rl3, an alkyl group, or 
a phenyl group, a napthyl group; R3 is H, a nitro group, a 
halogen atom, an amino group, a hydroxy group, or a cyano 
group; R4 is H, F, an alkyl group, an alkenyl group, an 
alkynyl group, a trialkylsilyl group or an alkoxy group; R5 
is a Cl_l5 alkyl group, an allyl group, a benZyl group or a 
propargyl group; R6, R7 and R8 are independently a C1_l5 
alkyl group, a C2_ 15 alkenyl group, a C2_l5 alkynyl group, a 
phenyl group, a napthyl group or a (CH2)qRl5 group, 
Wherein q is an integer betWeen 1 and 15 and R15 is a 
hydroxy group, alkoxy group, an amino group, an alky 
lamino group, a dialkylamino group, a halogen atom, a 
cyano group or a nitro group; R9 is a hydrogen, an alkyl 
group, an alkenyl group, an alkynyl group, an alkoxy group, 
a phenoxy group, a napthyloxy group, or an acyloxy group; 
R11 is hydrogen, an alkyl group, an alkenyl group and 
(CHZ)LNRI6Rl7 Wherein L may be an integer ranging from 
1*30 and R16 and R17 are independently the same or differ 
ent and are hydrogen, a Cl_l5 alkyl group, a C2_l5 alkenyl 
group, a C2_l5 alkynyl group, a phenyl group, a napthyl 
group, a (CH2)YRl8 group, a (CH2)YC(O)Rl8 group or a 
(CH) YCO2R18 Wherein Y may be an integer ranging from 1 
to 15 and R1 8 is a hydroxy group, a thiol group, an alkylthiol, 
a silyl group, an alkoxy group, an amino group, an alky 
lamino group, a dialkylamino group, a halogen atom, a 
cyano group, a nitro group. 
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